Testing a new CD73-targeting probe for imaging
Treatments studied
Part of Cancer clinical trials.
This early-phase trial tests a new imaging probe that targets a protein called CD73 on cells. It helps doctors see how the probe works in your body and if it could be used for diagnosis in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must agree to join the study and keep follow-up appointments.
- You cannot be pregnant or breastfeeding.
- You must not have severe liver or kidney problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new imaging agent called 68Ga-JH04 that is used with a PET/CT scan. The goal is to see how the agent travels through the body and how much radiation it gives off, which may help doctors better understand and treat your tumor.
This trial tests a new PET imaging agent that targets CD73, a protein found on many cancer cells. It may help doctors see tumors more clearly without chemotherapy or radiation before the scan.
This trial uses a special PET/CT scan to find breast cancer cells that have a certain marker (CD73). It may help doctors see the cancer more clearly before you start other treatments.
This trial tests a new imaging method (68Ga-DOTA-mPNE PET/CT) to see if it can help detect cancers. It's for people who haven't had chemotherapy or radiation yet and will have a biopsy or surgery.
This trial tests a special imaging agent (a nanobody probe) that targets a protein called CD147 on tumor cells. If you have a solid tumor like melanoma, liver, colorectal, pancreatic, breast, stomach, or lung cancer, the PET scan may help doctors see your cancer more clearly.
This study uses a special scan (molecular imaging) to see how well antibody-drug conjugates (ADCs) work in people with breast cancer. It may help doctors choose the right treatment for you.
Hear when a new Malignant Tumour trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.